Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown

Novo Nordisk shares fell 2.5% to DKK319.20 after Deutsche Bank flagged a continued US slowdown in the oral version of Wegovy. The update cites weaker prescription trends in its weekly GLP-1 tracker for Novo’s franchise. While not a full earnings event, the incremental demand signal is likely to pressure near-term growth expectations.

Analysis

The market is reacting to a channel-mix problem, not a franchise impairment. If the oral format is decelerating, the main implication is that the incremental patient pool is proving more price- and adherence-sensitive than bulls expected, which caps near-term upside to U.S. share gains and delays operating leverage in the obesity portfolio by 1-2 quarters.

Second-order, a weaker oral ramp is actually constructive for rivals that compete on convenience and access rather than pure efficacy. LLY keeps the cleaner relative-growth narrative, while telehealth/compounding intermediaries lose some of the “branded oral disruption” thesis; if branded oral uptake stays soft, the market may also reprice how much of NVO’s 2025-26 growth can come from the U.S. without another supply or pricing catalyst.

The contrarian read is that this is likely over-interpreted on a single tracker. Oral adoption is a late-stage funnel step, so weekly prescription noise can look like a trend before refill cohorts stabilize; what matters is whether injectable script growth, persistence, and payer access remain intact. The thesis is only broken if weakness spills into total GLP-1 volume or management trims full-year obesity guidance; otherwise this is a tactical sentiment headwind, not a structural thesis break.

Key Decisions for Investors

• No aggressive directional trade yet; treat this as a watch item into the next earnings update. The key falsifier is any downgrade to full-year GLP-1 growth or U.S. share commentary.
• If you want expression, favor a 3-6 month relative-value short NVO / long LLY pair. The pair works if oral softness reflects a broader U.S. demand inflection; stop if NVO stabilizes on refill growth or LLY disappoints on capacity.
• Use short-dated put spreads on NVO only if the stock re-tests support after the tracker-driven dip. Best risk/reward is a tactical catalyst trade into the next prescription data print, not a structural short.
• Watch compounding/telehealth beneficiaries such as HIMS only if branded GLP-1 access remains constrained; if branded demand weakens, that optionality fades quickly.
• Set an alert on U.S. weekly GLP-1 script trends over the next 4-8 weeks; a sustained inflection in total scripts would invalidate the negative read-through much faster than any single oral data point.